# Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

> **NCT05484583** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Affiliated Cancer Hospital & Institute of Guangzhou Medical University** · enrollment: 58 (estimated)

## Conditions studied

- Lung Cancer
- Extensive-stage Small-cell Lung Cancer
- Radiotherapy

## Interventions

- **DRUG:** Durvalumab + carboplatin/cisplatin + etoposide
- **RADIATION:** Consolidation radiotherapy
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05484583
- **Lead sponsor:** Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05484583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05484583, "Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05484583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*